Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project

The promise of “personalized medicine” guided by an understanding of each individual's genome has been fostered by increasingly powerful and economical methods to acquire clinically relevant information. We describe the operational implementation of prospective genotyping linked to an advanced clinical decision‐support system to guide individualized health care in a large academic health center. This approach to personalized medicine entails engagement between patient and health‐care provider, identification of relevant genetic variations for implementation, assay reliability, point‐of‐care decision support, and necessary institutional investments. In one year, approximately 3,000 patients, most of whom were scheduled for cardiac catheterization, were genotyped on a multiplexed platform that included genotyping for CYP2C19 variants that modulate response to the widely used antiplatelet drug clopidogrel. These data are deposited into the electronic medical record (EMR), and point‐of‐care decision support is deployed when clopidogrel is prescribed for those with variant genotypes. The establishment of programs such as this is a first step toward implementing and evaluating strategies for personalized medicine.

[1]  V. Fuster,et al.  Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle. , 2010, JAMA.

[2]  A. Bura,et al.  Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. , 2006, Blood.

[3]  William W Stead,et al.  Biomedical informatics: changing what physicians need to know and how they learn. , 2011, Academic medicine : journal of the Association of American Medical Colleges.

[4]  E. Topol,et al.  The case for routine genotyping in dual-antiplatelet therapy. , 2010, Journal of the American College of Cardiology.

[5]  A. de Boer,et al.  CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. , 2010, European heart journal.

[6]  R. Steinbrook,et al.  Opportunities and Challenges for the NIH — An Interview with Francis Collins , 2009 .

[7]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[8]  C. Møldrup,et al.  Lay perspective on pharmacogenomics: a literature review. , 2006, Personalized medicine.

[9]  A. Kastrati,et al.  Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement , 2010, Circulation.

[10]  E. Antman,et al.  Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. , 2010, JAMA.

[11]  N. Schork,et al.  Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. , 2011, JAMA.

[12]  Terri L. Edwards,et al.  Clinical and Translational Research Studios: A Multidisciplinary Internal Support Program , 2012, Academic medicine : journal of the Association of American Medical Colleges.

[13]  S. Kaul,et al.  ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association , 2010, Circulation.

[14]  M. Guyer,et al.  Charting a course for genomic medicine from base pairs to bedside , 2011, Nature.

[15]  G. Montalescot,et al.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study , 2009, The Lancet.

[16]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[17]  J. O’Connell,et al.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.

[18]  D. Masys.  Effects of current and future information technologies on the health care workforce. , 2002, Health affairs.

[19]  A. Issa,et al.  Assessing Patient Readiness for the Clinical Adoption of Personalized Medicine , 2009, Public Health Genomics.

[20]  R. Mckinnon,et al.  Consumers' views of pharmacogenetics--A qualitative study. , 2010, Research in social & administrative pharmacy : RSAP.

[21]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[22]  Francis Collins,et al.  Opportunities and challenges for the NIH--an interview with Francis Collins. Interview by Robert Steinbrook. , 2009, The New England journal of medicine.

[23]  Janet Woodcock,et al.  Pharmacogenetics--tailoring treatment for the outliers. , 2009, The New England journal of medicine.

[24]  G. Ginsburg,et al.  The path to personalized medicine. , 2002, Current opinion in chemical biology.

[25]  M. Okano,et al.  Cohort Study , 2020, Definitions.

[26]  D. Roden,et al.  Predicting Clopidogrel Response Using DNA Samples Linked to an Electronic Health Record , 2012, Clinical pharmacology and therapeutics.

[27]  Janine M. Traulsen,et al.  ‘I’m Happy if I Can Help’ , 2008, Public Health Genomics.

[28]  A. D. Blackader.  PATIENTS AND PHYSICIANS. , 1929, Canadian Medical Association journal.

[29]  B. Gersh.  Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction: Results From the French Registry of Acute ST-Elevation and Non–ST-Elevation Myocardial Infarction (FAST-MI) Registry , 2012 .

[30]  Deepak L. Bhatt,et al.  Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. , 2010, The New England journal of medicine.

[31]  P. Barragan,et al.  Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. , 2010, Journal of the American College of Cardiology.

[32]  J. Brockmöller,et al.  Patients' and physicians' perspectives on pharmacogenetic testing. , 2006, Pharmacogenomics.

[33]  S. Trent Rosenbloom,et al.  MyHealthAtVanderbilt: policies and procedures governing patient portal functionality , 2011, J. Am. Medical Informatics Assoc..

[34]  T. MacDonald,et al.  Antiplatelet drug interactions , 2010, Journal of internal medicine.

[35]  J. Ferrières,et al.  Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.

[36]  I. Xanthopoulou,et al.  Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. , 2011, JACC. Cardiovascular interventions.

[37]  Y. Jeong,et al.  Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. , 2011, JACC. Cardiovascular interventions.

[38]  E. Antman,et al.  Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis , 2010, The Lancet.

[39]  Issam Zineh,et al.  DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA. , 2010, Pharmacogenomics.

[40]  J. Ferrières,et al.  Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction: Results From the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry , 2011, Circulation.

[41]  Richard Shen,et al.  Medium- to high-throughput SNP genotyping using VeraCode microbeads. , 2009, Methods in molecular biology.

[42]  I. Björnsdottir,et al.  A lay prescription for tailor-made drugs--focus group reflections on pharmacogenomics. , 2005, Health policy.

[43]  G. Montalescot,et al.  Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. , 2010, Journal of the American College of Cardiology.

[44]  F. Schmidt.  Meta-Analysis , 2008 .

[45]  R. Pai,et al.  Review Article: Combination of Clopidogrel and Proton Pump Inhibitors: Implications for Clinicians , 2010, Journal of cardiovascular pharmacology and therapeutics.

[46]  P. Gurbel,et al.  First Analysis of the Relation Between CYP2C19 Genotype and Pharmacodynamics in Patients Treated With Ticagrelor Versus Clopidogrel: The ONSET/OFFSET and RESPOND Genotype Studies , 2010, Circulation. Cardiovascular genetics.

[47]  G. Montalescot,et al.  High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). , 2011, JACC. Cardiovascular interventions.

[48]  Shashi Amur,et al.  Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use , 2008, Pharmacotherapy.

[49]  D. Roden,et al.  Development of a Large‐Scale De‐Identified DNA Biobank to Enable Personalized Medicine , 2008, Clinical pharmacology and therapeutics.

[50]  W. Newman,et al.  Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. , 2007, Pharmacogenomics.